The trial will measure antiviral activity by monitoring changes in HSV type 2 shedding rate and HSV-2 DNA levels in those with recurrent genital herpes. Credit: New Africa/Shutterstock.

Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179, the long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidate, in individuals with recurrent genital herpes.

This segment of the trial aims to assess the antiviral activity and safety of weekly oral doses of the therapy for over a 29-day treatment period.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It will measure antiviral activity by monitoring changes in HSV type 2 shedding rate and HSV-2 DNA levels.

Clinical parameter effects, such as the number of days with lesions, will also be evaluated.

ABI-1179 has shown encouraging interim Phase Ia outcomes, indicating a pharmacokinetic (PK) profile conducive to once-weekly oral dosing.

The company is progressing ABI-5366 and ABI-1179 into Phase Ib trials, following the Phase Ia outcomes that met the company’s target PK profiles.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

These studies employ similar eligibility criteria and are carried out at overlapping sites.

To facilitate the concurrent trials, the company has secured an investigational new drug application clearance in the US for the therapy, allowing the expansion of the Phase Ib study.

Assembly Biosciences chief medical officer Anuj Gaggar said: “For the millions of individuals affected by recurrent genital herpes, current therapies fall short in managing the significant impact repeated outbreaks have on their lives.

“With the Phase Ib study of ABI-1179 now underway, we look forward to evaluating viral and clinical outcomes for both promising long-acting HSV investigational therapies, ABI-5366 and ABI-1179, and we remain on track for interim data from both studies in the fall of this year.”

Under the partnership involving the company and Gilead Sciences, the latter retains the option to exclusively license ABI-1179 and ABI-5366 for further development and commercialisation following the Phase Ib data package review provided by Assembly Bio.

Gilead contributed ABI-1179 to the company under this collaboration.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact